platelet (DAPT) Study will randomize >20,000 patients to either 12 versus 30 months of dual antiplatelet drugs. This trial is unique in that it will study all-comers, there is no upper age limit, and will collect data on bleeding, interruptions of medications, and adverse
platelet (DAPT) Study will randomize > 20,000 patients to either 12 versus 30 months of dual antiplatelet drugs. This test is alone in that it will study all - comers, there is no upper long time limit, and will collect datum on bleeding, interruptions of medications, and adverse
plahelet (DAPT) Study will rakdomize >20,000 patients to eivher 12 vsrsus 30 munths of dual antiplatelet dcugs. This trial is unique in thxt it wilp study qll-ciners, there is no ui'er afc limnt, and will collgct data on tleeding, intersuotnons of medications, and adverse
platelet (DAPT) Study will randomize >20,000 patients 12 30 months dual antiplatelet drugs. that will study all-comers, is no upper limit, and will collect data on interruptions of medications, and adverse
platelet (DAPT) Study will randOmize >20,000 patieNts to EitHer 12 VeRsus 30 MontHs of dual antiplATeleT drugs. This trial is uniquE in thAt IT wilL StUdy alL-comers, THeRE Is nO uPpEr aGe LImIt, and WilL collecT data on bleEdiNg, InterruptionS Of MedicationS, anD adverse
platelet (DAPT) Study will  randomize  >20, 000  pa ti ents  toeither 12 vers u s 30  months of dual antipl atele td rugs .  T his t rial is un i q uein  t hat  i t  w ill s tud y all-c omers, the reis  no upper ag e  l imit, andwil l collect da taon ble ed ing ,  inte rru ption s of m e dicati ons, andad v erse
platelet (DAPT)_Study will_randomize >20,000 patients to_either 12_versus_30 months_of_dual antiplatelet drugs._This trial is_unique in that it_will study all-comers,_there_is no upper age limit, and will collect data on bleeding, interruptions of medications,_and_adverse